A synchronous hepatocellular carcinoma and renal cell carcinoma treated with radio-frequency ablation.
10.3350/cmh.2014.20.3.306
- Author:
Yoon Serk LEE
1
;
Jeong Han KIM
;
Hyeon Young YOON
;
Won Hyeok CHOE
;
So Young KWON
;
Chang Hong LEE
Author Information
1. Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea. 93haan@hanmail.net
- Publication Type:Case Reports
- Keywords:
Hepatocellular carcinoma;
Renal cell carcinoma;
Radiofrequency ablation
- MeSH:
Carcinoma, Hepatocellular/complications/*diagnosis/therapy;
Carcinoma, Renal Cell/complications/*diagnosis/therapy;
Catheter Ablation;
Humans;
Kidney Neoplasms/complications/*diagnosis/therapy;
Liver Cirrhosis/complications/*diagnosis;
Liver Neoplasms/complications/*diagnosis/therapy;
Magnetic Resonance Imaging;
Male;
Middle Aged;
Tomography, X-Ray Computed
- From:Clinical and Molecular Hepatology
2014;20(3):306-309
- CountryRepublic of Korea
- Language:English
-
Abstract:
Radio-frequency ablation (RFA) is a curative treatment for hepatocellular carcinoma (HCC). Percutaneous RFA has been shown to be beneficial for patients with small renal cell carcinoma (RCC) lacking indications for resection. We experienced the case of a 53-year-old male who had conditions that suggested HCC, RCC, and alcoholic liver cirrhosis. Abdominal contrast-enhanced computed tomography (CT) and magnetic resonance image showed liver cirrhosis with 2.8 cm ill-defined mass in segment 2 of the liver and 1.9 cm hypervascular mass in the left kidney. These findings were compatible with the double primary cancers of HCC and RCC. Transarterial chemoembolization (TACE) was performed to treat the HCC. After the TACE, a focal lipiodol uptake defect was noticed on a follow up CT images and loco-regional treatment was recommended. Therefore, we performed RFAs to treat HCC and RCC. There was no evidence of recurrence in the follow up image after 1 month.
